Science & Technology
Developing a topical beta blocker formulation as a targeted therapeutic for infantile hemangioma
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41HL177866-01A1
Award Ceiling
$307K
Award Floor
$307K
Close Date
May 31, 2026
77 days leftTotal Funding
$307K
Expected Awards
1
Posted Date
Jun 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41HL177866-01A1
Description
STTR Phase Phase I award: "Developing a topical beta blocker formulation as a targeted therapeutic for infantile hemangioma" awarded to ARKAYLI BIOPHARMA, INC. in MADISON, Wisconsin. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $306,804. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.